A Phase 1 interventional study of varegacestat and Itraconazole (200 mg) in Healthy Volunteer, sponsored by Immunome, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-11.
Sponsored by Immunome, Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open label, fixed sequence, 1-way crossover drug-drug interaction (DDI) study in healthy participants.
This is a phase 1, open-label, fixed sequence, 1-way crossover study examining the effect of itraconazole on the pharmacokinetics, safety and tolerability after varegacestat single dose administration to healthy participants. This is a 2-period study. In period 1 a single dose of varegacestat will be administered with PK evaluated predose and up to 192 hours postdose. There will be a 14 -day washout between period 1 and period 2. In period 2, itraconzole will be administered once daily for 18 consecutive days. Beginning on Day 4 of Period 2 a single dose of varegacestat will be administered 30 minutes after itraconazole dosing. Blood samples for PK will be collected prior to varegacestat dosing and up to 744 hours post varegacestat dosing for varegacestat and its metabolite.
Immunome, Inc. is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: varegacestat administration for PK followed by Period 2: itraconazole and varegacestat administration for PK and DDI
Drug: varegacestat · Drug: Itraconazole (200 mg)
Experimental intervention
Intervention to evaluate DDI with experimental intervention
Effect of itraconazole on the PK of varegacestat in healthy participants.
AUC0-t for varegacestat administered with and without itraconazole.
Time frame: Up to 5 weeks
Effect of itraconazole on the PK of varegacestat in healthy participants.
AUC0-inf for varegacestat administered with and without itraconazole.
Time frame: Up to 5 weeks
Effect of itraconazole on the PK of varegacestat in healthy participants.
Cmax for varegacestat administered with and without itraconazole.
Time frame: Up to 5 weeks
Effect of itraconazole on the PK of varegacestat in healthy participants.
Tmax for varegacestat administered with and without itraconazole.
Time frame: Up to 5 weeks
Safety and tolerability of varegacestat in the presence of itraconazole in healthy participants.
Number of subjects who experience treatment-emergent adverse events (TEAEs)
Time frame: Up to 2 months
Safety and tolerability of varegacestat in the presence of itraconazole in healthy participants.
Number of subjects who experience abnormalities in clinical laboratory tests such as serum chemistry and hematology
Time frame: Up to 2 months
Safety and tolerability of varegacestat in the presence of itraconazole in healthy participants.
Number of subjects who experience 12-lead ECG abnormalities
Time frame: Up to 2 months
Ctrough of itraconazole and hydroxy-itraconazole in combination with varegacestat in healthy participants.
Ctrough. values on prior to dosing itraconazole
Time frame: Up to 5 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Dec 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BMS-986115 · Itraconazole